Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00047255 · ClinicalTrials.gov registry record · Phase 3
Docetaxel and Trastuzumab With or Without Carboplatin in Treating Women With HER2-Positive Breast Cancer
A Phase 3 study, sponsored by Jonsson Comprehensive Cancer Center.
- Completed
- Registry status
- Phase 3
- Development phase
- 263
- Enrollment target
NCT00047255 is a Phase 3 study that has completed, run by Jonsson Comprehensive Cancer Center. The registered enrollment target is 263 participants.
The verdict
NCT00047255, a Phase 3 study, has completed, sponsored by Jonsson Comprehensive Cancer Center.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 263 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Monoclonal antibodies such as trastuzumab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. It is not yet known if docetaxel and trastuzumab are more effective with or without carboplatin in treating women who have HER2-positive breast cancer. PURPOSE: Randomized phase III trial to study the effectiveness of combining docetaxel and trastuzumab with or without carboplatin in treating women who have HER2-positive stage IIIB or stage IV breast cancer.
Interventions
- DRUG Docetaxel
- DRUG carboplatin
- DRUG docetaxel
- BIOLOGICAL trastuzumab
- BIOLOGICAL trastuxumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 263 participants |
| Start Date | 2002-05 |
| Est. Completion | 2010-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00047255
The ClinicalTrials.gov registry entry for NCT00047255 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 263 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Jonsson Comprehensive Cancer Center, which has 321 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Docetaxel is the first listed.
NCT00047255 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00047255 about?
NCT00047255 is a clinical study titled "Docetaxel and Trastuzumab With or Without Carboplatin in Treating Women With HER2-Positive Breast Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Monoclonal antibodies such as trastuzumab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. It is not yet known ...
What is the current status of trial NCT00047255?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 263 participants. The study started on 2002-05. Estimated completion is 2010-04.
What interventions are being tested in trial NCT00047255?
The interventions under investigation include: Docetaxel (DRUG), carboplatin (DRUG), docetaxel (DRUG), trastuzumab (BIOLOGICAL), trastuxumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT00047255?
This trial is sponsored by Jonsson Comprehensive Cancer Center, which has 321 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.